Introducing the new AltIndexLearn more
$0 100%Beat EPS +230.8%
Total revenue, Q2 '25 (USD).

Did Tvardi Therapeutics Beat Earnings?

Tvardi Therapeutics (TVRD) reported Q2 '25 revenue of $0, down 100.0% year-over-year, with reported EPS of $0.51. That topped the $-0.39 analyst estimate by 230.8% — an earnings beat.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Tvardi Therapeutics’s job postings, web traffic, and employee business outlook. See the full TVRD stock analysis or the earnings calendar for upcoming reports.

Tvardi Therapeutics Quarterly Financial Trends (USD)

MetricQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Revenue990,0002.6M1.5M2.6M
Gross margin-0.5%97.1%97.1%100.0%
Operating margin-724.6%-222.1%-742.4%-92.9%
Net income-7M-5.5M-13M-4.9M4.2M-5.5M-7.3M-6.8M
Net margin-703.8%-215.7%-873.3%-191.0%
EPS$0.51

Tvardi Therapeutics Earnings Trend Analysis

Over the eight quarters from Q2 '24 to Q1 '26, Tvardi Therapeutics’s quarterly revenue moved from $990,000 to $0. Tvardi Therapeutics has beaten Wall Street EPS estimates in 1 of its last 1 reported quarters.

When Is Tvardi Therapeutics’s Next Earnings Date?

Tvardi Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q2 '25. For the confirmed upcoming date — and every other company reporting soon — see the TVRD earnings calendar.

Frequently Asked Questions: Tvardi Therapeutics Earnings

Tvardi Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Tvardi Therapeutics reported Q2 '25 EPS of $0.51 on revenue of $0 (-100.0% YoY). Tvardi Therapeutics beat estimates, reporting $0.51 vs. the $-0.39 estimate.

Tvardi Therapeutics reported Q2 '25 revenue of $0, down 100.0% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the TVRD AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.